-Β Announced robust preclinical data supporting the unique three-pronged mechanism of action of micvotabart...
BOSTON, May 14, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company...
Gene signatures associated with increased efficacy of micvotabart pelidotin (MICVO) due to greater linker...
BOSTON, April 02, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company...
Expression data from patient-derived xenograft (PDX) mouse models exposed to micvotabart pelidotin (MICVO...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Subscribe to Ad free and enjoy an ad-free experience
Try Now
Keep the Ads